IASLC Mesothelioma Staging Project - Reduced Set of Data Elements for Proposals for Change to 8th Edition TNM 7/7/2013

Size: px
Start display at page:

Download "IASLC Mesothelioma Staging Project - Reduced Set of Data Elements for Proposals for Change to 8th Edition TNM 7/7/2013"

Transcription

1 Page 1 of 16 Patient Characteristics form (3 variables) Disease Description form (6 variables) Pre-treatment/Evaluative TNM form - Pre-Treatment/Evaluative Thickness and Effusions form - Pre-Treatment/Evaluative Invasion form - Pre-Treatment/Evaluative N form - Pre-Treatment/Evaluative M form Treatment form (15 variables) Post-surgical TNM form - Post-Surgical Invasion form - Post-Surgical N form - Post-Surgical M form Follow Up form

2 Page of 16 Patient Characteristics and Disease Description forms Field # Field Name Oracle column Length 1 Patient birth date BIRTHDATE DDMMMYYYY Values/Notes DDD: in (JAN, FEB, MAR, APR, MAY, JUN, JUL, AUG, SEP, OCT, NOV, DEC) Sites may elect to provide only year of birth - or, provide the age at diagnosis in lieu of birth year -- if this is a requirement for release of the data by the local ethics review board. Substituting age at diagnosis for birth date or year is not advisable for sites which intend to export and analyze their data locally. Sex SEX 1 No selection=null, Male=M, Female=F, No data=u 3 Race RACE No selection=null, Asian=ASIAN, Black or African American=BLACK, White 7 or Caucasian=WHITE, American Indian/Alaskan Native/Pacific Islander=PACIFIC, Other/Mixed/Uncertain=UNKNOWN 4 Laterality LATERALITY No selection=null, Right=R, Left=L, Bilateral=BI, No data=nd Histologic No selection=null, Diffuse malignant mesothelioma: Epithelioid Type/Subtype mesothelioma=dmmepi, Diffuse malignant mesothelioma: Sarcomatoid (*Note: If value is mesothelioma=dmmsarc, Diffuse malignant mesothelioma: Desmoplastic 'Other' or 'No mesothelioma=dmmdesmo, Diffuse malignant mesothelioma: Biphasic data', then the mesothelioma=dmmbi, Diffuse malignant mesothelioma: NOS=DMMNOS, following error Localized malignant mesothelioma: Epithelioid mesothelioma=lmmepi, messages is Localized malignant mesothelioma: Sarcomatoid displayed: Cases mesothelioma=lmmsarco, Localized malignant mesothelioma: for which the Desmoplastic mesothelioma=lmmdesmo, Localized malignant histologic type is mesothelioma: Biphasic mesothelioma=lmmbi, Localized malignant specified as mesothelioma: NOS=LMMNOS, Well differentiated papillary 'Other' or for mesothelioma=wdpm, Malignant mesothelioma, NOS=MMNOS, which no Other=OTH, No data=nd histologic type is

3 Page 3 of 16 Patient Characteristics and Disease Description forms Field # 6 7 Field Name Other histologic type Localized vs diffuse? 8 Pleomorphic? 9 Date of pathologic diagnosis % Oracle column OTHERHISTO TYPE LOCALVSDIFF USE PLEOMORPH IC DATEDX Length 100 alphanumeric 9 No selection=null, Localized=L, Diffuse=D, No data=nd, Not applicable=na No selection=null, Yes=Y, No=N, No data=nd Derived variable, format DDMMMYYYY Values/Notes "Other histologic type" entered if Histologic Type/Subtype is 'Malignant mesothelioma, NOS' or 'Other' "Localized vs diffuse" entered if Histologic Type/Subtype is 'Malignant mesothelioma, NOS' or 'Other' % Date of diagnosis is a derived variable which is equal to: 1) the date of histology if histologic proof of malignancy is obtained or ) the date of cytology, if the diagnosis is based on solely on cytologic proof of malignancy. The data contributor may elect to provide year only for the date of diagnosis and to provide "delta times" (days elapsed since the date of diagnosis) for all other date fields.

4 Page 4 of 16 Pre-treatment/Evaluative TNM form Oracle Field # Field Name column Length 10 T Status TSTATUS 5 Values/Notes No selection=null, T1a=TIa, T1b=T1b, T1, NOS=T1NOS, T=T, T3=T3, T4=T4, No data=nd 11 N Status NSTATUS No selection=null, N0=N0, N1=N1, N=N, N3=N3, Nx=NX, No data=nd 1 M Status MSTATUS No selection=null, M0=M0, M1=M1, No data=nd 13 Stage STAGE NULL (if TNM form not submitted), IA=1A, IB=1B, 1=I, II=, 3=III, 4=IV, X=Unable to assess, Post-surgical TNM form Field # Field Name Oracle column Length Values/Notes 14 T Status PTSTATUS 5 No selection=null, T0=T0, T1a=TIa, T1b=T1b, T1, NOS=T1NOS, T=T, T3=T3, T4=T4, Tx=TX, No data=nd 15 N Status PNSTATUS No selection=null, N0=N0, N1=N1, N=N, N3=N3, Nx=NX, No data=nd 16 M Status PMSTATUS No selection=null, M0=M0, M1=M1, No data=nd 17 Stage PSTAGE NULL (if TNM form not submitted), IA=1A, IB=1B, 1=I, II=, 3=III, 4=IV, X=Unable to assess,

5 Page 5 of 16 Pre-Treatment/Evaluative Thickness and Effusions form Field # Field Name Oracle column Le ngth Values/Notes 18 Pleural Thickening PTHICKENING No selection=null, Minimal=MIN, Rind-like=RIND, 4 Nodular=NOD, No data=nd 19 Pleural Plaques PPLAQUES No selection=null, Yes, non-calcified=ncal, Yes, 4 calcified=cal, Yes, calcification not specified=y, No data=nd Measured - Upper level 0 PTUPPER of pleura? 1 Not checked=y, checked=n Maximum thickness - 1 Upper level of pleura PTUPPERSIZE Measured - Middle level of pleura? PTMID 1 Not checked=y, checked=n Maximum thickness - 3 Middle level of pleura PTMIDSIZE Measured - Lower level 4 PTLOWER of pleura? 1 Not checked=y, checked=n Maximum thickness - 5 Lower level of pleura PTLOWERSIZE Pleural effusion PLEUREFF No selection=null, None=NONE; Present, right side=r; 4 Present,left side=l; Present, both sides=both, Present, side not specified=y; No data=nd 7 Cytology (if present) PLEURCYT No selection=null, Positive=POS, Negative=NEG, No 3 data=nd 8 Pericardial effusion PERIEFF No selection=null, No=N; Yes, with positive 4 cytology=ypos; Yes, with negative cytology=yneg; Yes, without cytology results=y; No data=nd

6 Page 6 of 16 IASLC M Pre-Treatment/Evaluative Invasion form Field Oracle column Field Name # Length Values/Notes 9 Ipsilateral Parietal Pleural Invasion PPLEURA No selection=null, N=No, Yes=Y, No data=nd 30 Ipsilateral Visceral Pleural Invasion 31 Fissural Involvement VPLEURA FISSURE No selection=null, N=No, Yes=Y, No data=nd No selection=null, N=No, Yes=Y, No data=nd "Fissural involvement" entered if Visceral Pleural Invasion='Yes' 3 Single focus vs confluent CONFLUENT No selection=null, Single focus=n, Confluent tumor=y, No data=nd "Single focus vs confluent" entered if Visceral Pleural Invasion='Yes' 33 Chest Wall / Endothoracic Fascia Invasion CHESTWALL 5 34 Extent of Chest Wall / Endothoracic Fascia Invasion CHESTWALLEXT 4 No selection=null, No=N, Pleura and endothoracic fascia only=y1, Fascia and chest wall muscle=y; Fascia, chest wall muscle, and ribs=y3, Yes, no further data=y; No data=nd No selection=null, None=NONE, Single focus=y1, Diffuse or multifocal=y; Yes, no further data=y; No data=nd "Extent " entered if Chest Wall / Endothoracic Fascia Invasion = 'Pleura and endothoracic fascia only' or 'Fascia and chest wall muscle' or 'Fascia, chest wall muscle, and ribs' 35 Brachial Plexus Nerve Invasion BRACHPLEX No selection=null, No=N, Yes=Y, No data=nd Contralateral Pleural Invasion (Direct 36 Extension) CONTPLEURA No selection=null, N=No, Yes=Y, No data=nd 37 Lung Parenchyma Invasion LUNGPARENCH No selection=null, No=N, Yes=Y, No data=nd 38 Mediastinal Invasion MEDIASTINUM No selection=null, No=N, Mediastinal fat=y1, Mediastinal organs=y, No data=nd 39 Pericardial Invasion PERICARDIUM No selection=null, No=N, Possible=P, Yes=Y, No data=nd 40 Heart Muscle Invasion HEARTMUSCLE No selection=null, No=N, Yes=Y, No data=nd 41 Oesophageal Invasion ESOPHAGUS No selection=null, No=N, Yes=Y, No data=nd 4 Diaphragm Invasion DIAPHRAGM No selection=null, No=N, Possible=POSS, Probable=PROB, 5 Definite=DEF, Transmural=TRSM, No data=nd 43 Spinal Invasion SPINE No selection=null, No=N, Yes=Y, No data=nd

7 Page 7 of 16 Pre-Treatment/Evaluative N form Field # Field Name Oracle column Length Values 44 Nodal map used: NODALMAP No selection = NULL, IASLC-009 = IASLC, 5 None = NONE, No data = ND 45 Low cervical, supraclavicular and sternal notch, Station #1R IN1R 3 46 Low cervical, supraclavicular and sternal notch, Station #1L IN1L 3 47 Upper paratracheal, Station #R INR 3 48 Upper paratracheal, Station #L INL 3 49 Pre-vascular, Station #3AR IN3AR 1 50 Pre-vascular, Station #3AL IN3AL 1 51 Retrotracheal, Station #3P IN3P 1 5 Lower paratracheal, Station #4R IN4R 1 53 Lower paratracheal, Station #4L IN4L 1 54 Sub-aortic, Station #5 IN Para-aortic, Station #6 IN Subcarinal, Station #7 IN Paraoesophageal, Right, Station #8R IN8R 3 58 Paraoesophageal, Left, Station #8L IN8L 3 59 Pulmonary ligament, Right, Station #9R IN9R 3 60 Pulmonary ligament, Left, Station #9L IN9L 3 61 Hilar, Right, Station #10R IN10R 3 No data = ND, 6 Hilar, Left, Station #10L IN10L 3 + = POS, 63 Interlobar, Right, Station #11R IN11R 3 - = NEG 64 Interlobar, Left, Station #11L IN11L 3 65 Lobar, Right, Station #1R IN1R 3 66 Lobar, Left, Station #1L IN1L 3 67 Segmental, Right, Station #13R IN13R 3 68 Segmental, Left, Station #13L IN13L 3 69 Subsegmental, Right, Station #14R IN14R 3 70 Subsegmental, Left, Station #14L IN14L 3 71 Internal Mammary, Right ININTMAMMARYR 3 7 Internal Mammary, Left ININTMAMMARYL 3 73 Pericardial, Right INPERICARDIALR 3 74 Pericardial, Left INPERICARDIALL 3 75 Peridiaphragmatic, Right INPERIDIAPGHRR 3 76 Peridiaphragmatic, Left INPERIDIAPGHRL 3 77 Intercostal, Right ININTERCOSTALR 3 78 Intercostal, Left ININTERCOSTALL 3 79 Retrocrual, Right INRETROCRUALR 3 80 Retrocrual, Left INRETROCRUALL 3

8 Page 8 of 16 Pre-Treatment/Evaluative M form Field # Field Name Oracle column Length Values Notes 81 Contralateral pleura METPLEURA 8 Contralateral lung METLUNG 83 Peritoneum METPERITONEUM 84 Intra-abdominal METINTRAABDOM 85 Bone METBONE 6 86 Liver parenchyma METLIVER 87 Brain METBRAIN 88 Other distant lymph nodes METOTHERDLN 89 Contralateral pleura - Biopsied or resected METPLEURABX 90 Contralateral lung - Biopsied or resected METLUNGBX 91 Peritoneum - Biopsied or resected METPERITONEUMBX 9 Intra-abdominal - Biopsied or resected METINTRAABDOMBX 93 Bone - Biopsied or resected METBONEBX 6 94 Liver parenchyma - Biopsied or resected METLIVERBX 95 Brain - Biopsied or resected METBRAINBX 96 Other distant lymph nodes - Biopsied or resected METOTHERDLNBX 97 Specify, Other distant sites SPECIFYODSITES 00 alphanumeric 98 Other metastasis OTHERMETASTASIS 00 No selection=null, Absent=ABSENT, Single=SINGLE, Multiple=MULT, Present=PRES, No data=nd No selection=null, Yes, resected=yres; Yes, biopsied, positive for malignancy=ybxpos; Yes, biopsied, negative for malignancy=ybxneg; No=N, No data=nd (optional additional information, when site of lesion is: SINGLE, MULT, or PRES) alphanumeric Document presence, number of lesions, clinical certainty factor, and whether biopsied/resected for any other sites of metastasis not listed above

9 Page 9 of 16 Treatment form Field # Field Name Oracle column Length Values Notes No selection=null; No data=nd -> if 'None' or 'No data' is selected, skip to First Treatment in Sequence None=NONE; IF TREATMENT(FINALPROC) in ('NONE') - only Pre-Surgical forms are applicable 99 Final surgical procedure FINALPROC 1 Exploration, no pleurodesis (no resection)=exp; Exploration, pleurodesis only (no resection)=exppleurod Partial pleurectomy=ppleur; Pleurectomy /decortication=pd; Extended pleurectomy /decortication=extpd; Extrapleural pneumonectomy=epp; IF TREATMENT(FINALPROC) in ('EXP' 'EXPPLEUROD' 'PPLEUR' 'PD' 'EXTPD' 'EPP' 'OTHER') - Both Pre and Post-Surgical forms are applicable Other=OTHER; 100 Date of final procedure OPDATE DDMMMYYYY 101 Surgical approach (final procedure) SRGAPPROACH 5 No selection=null, None=NONE, Median Sternotomy=STERN, Thoracotomy=THOR, VATS=VATS, No data=nd 10 Diaphragm resected? RES_DIAPH 103 Diaphragm reconstructed? RECON_DIAPH 104 Pericardium resected? RES_PERI No selection=null, Yes=Y, No=No, 105 Pericardium reconstructed? RECON_PERI No data=nd 106 Chest wall resected? RES_CW 107 Chest wall reconstructed? RECON_CW DDD in (JAN, FEB, MAR, APR, MAY, JUN, JUL, AUG, SEP, OCT, NOV, DEC)

10 Page 10 of 16 Treatment form Oracle column Field # Field Name Length Values Notes 108 Other ipsilateral lung resection OTHRESECT 5 No selection=null, None=NONE, Segmentectomy=SEG, Wedge Resection=WEDGE, Lobectomy=LOBE, Bilobectomy=BILO, Pneumonectomy=PNEU, Other=OTH, No data=nd No selection=null, R1 (Microscopic residual 109 Completeness of resection RESCOMP tumor)=r1, R (Macroscopic residual tumour)=r, No data=nd Completeness of resection is entered if any of the following conditions are met: 1) Final procedure is not in (Select, None, No data) ) Diaphragm, pericardium, or chest wall is resected 3) Other ipsilateral lung resection is not in (Select, None, No data) 110 First treatment in sequence TRT Second treatment in sequence TRT 5 No selection=null, Surgery=SURG, Systemic therapy=sys, Radiation therapy=rt, Radiation and systemic therapy=rtsys, None=NONE, No data=nd 11 Third treatment in sequence TRT Total dose radiation (Gy) TOTRAD 4 Integer, RT data collected only if RT or RTSYS is indicated as first, second, or third treatment in sequence

11 Page 11 of 16 Post-Surgical Invasion form Field Oracle column Field Name # Length Values/Notes 114 Ipsilateral Parietal Pleural Invasion P_PPLEURA No selection=null, N=No, Yes=Y, No data=nd 115 Ipsilateral Visceral Pleural Invasion 116 Fissural Involvement PVPLEURA PFISSURE No selection=null, N=No, Yes=Y, No data=nd No selection=null, N=No, Yes=Y, No data=nd "Fissural involvement" entered if Visceral Pleural Invasion='Yes' 117 Single focus vs confluent PCONFLUENT No selection=null, Single focus=n, Confluent tumor=y, No data=nd "Single focus vs confluent" entered if Visceral Pleural Invasion='Yes' 118 Chest Wall / Endothoracic Fascia Invasion PCHESTWALL Extent of Chest Wall / Endothoracic Fascia Invasion PCHESTWALLEXT 4 No selection=null, No=N, Pleura and endothoracic fascia only=y1, Fascia and chest wall muscle=y; Fascia, chest wall muscle, and ribs=y3, Yes, no further data=y; No data=nd No selection=null, None=NONE, Single focus=y1, Diffuse or multifocal=y; Yes, no further data=y; No data=nd "Extent " entered if Chest Wall / Endothoracic Fascia Invasion = 'Pleura and endothoracic fascia only' or 'Fascia and chest wall muscle' or 'Fascia, chest wall muscle, and ribs' 10 Brachial Plexus Nerve Invasion PBRACHPLEX No selection=null, No=N, Yes=Y, No data=nd Contralateral Pleural Invasion (Direct 11 Extension) PCONTPLEURA No selection=null, N=No, Yes=Y, No data=nd 1 Lung Parenchyma Invasion PLUNGPARENCH No selection=null, No=N, Yes=Y, No data=nd 13 Mediastinal Invasion PMEDIASTINUM No selection=null, No=N, Mediastinal fat=y1, Mediastinal organs=y, No data=nd 14 Pericardial Invasion PPERICARDIUM No selection=null, No=N, Yes, non-transmural=y1, Yes, transmural=y, Yes, no further data=y, No data=nd. 15 Heart Muscle Invasion PHEARTMUSCLE No selection=null, No=N, Yes=Y, No data=nd 16 Oesophageal Invasion PESOPHAGUS No selection=null, No=N, Yes=Y, No data=nd

12 Page 1 of 16 Post-Surgical Invasion form Field # Field Name Oracle column Length 17 Diaphragm Invasion PDIAPHRAGM 5 Values/Notes No selection=null, No=N, Y1MUSCLE=Muscle only; YPERIT=Muscle plus adjacent peritoneum; Y3ABDOM=Muscle plus adjacent peritoneum plus adjacent abdominal organ, Y4DIFFUSE=Muscle plus diffuse peritoneal, no ascites; Y5ASCITES=Muscle plus diffuse peritoneal with ascites; Y=Yes, no further data, No data=nd. 18 Spinal Invasion PSPINE No selection=null, No=N, Yes=Y, No data=nd 19 Pleural effusion PPLEUREFF No selection=null, None=NONE; Present, right side=r; Present,left 4 side=l; Present, both sides=both, Present, side not specified=y; No data=nd 130 Cytology (if present) PPLEURCYT 3 No selection=null, Positive=POS, Negative=NEG, No data=nd 131 Pericardial effusion PPERIEFF 4 No selection=null, No=N; Yes, with positive cytology=ypos; Yes, with negative cytology=yneg; Yes, without cytology results=y; No data=nd

13 Page 13 of 16 Post-Surgical N form Field # Field Name Oracle column Length Values 13 Nodal map used: PNODALMAP No selection = NULL, IASLC-009 = IASLC, 5 None = NONE, No data = ND 133 Low cervical, supraclavicular and sternal notch, Station #1R PN1R Low cervical, supraclavicular and sternal notch, Station #1L PN1L Upper paratracheal, Station #R PNR Upper paratracheal, Station #L PNL Pre-vascular, Station #3AR PN3AR Pre-vascular, Station #3AL PN3AL Retrotracheal, Station #3P PN3P Lower paratracheal, Station #4R PN4R Lower paratracheal, Station #4L PN4L 3 14 Sub-aortic, Station #5 PN Para-aortic, Station #6 PN Subcarinal, Station #7 PN Paraoesophageal, Right, Station #8R PN8R Paraoesophageal, Left, Station #8L PN8L Pulmonary ligament, Right, Station #9R PN9R Pulmonary ligament, Left, Station #9L PN9L Hilar, Right, Station #10R PN10R 3 No data = ND, 150 Hilar, Left, Station #10L PN10L 3 + = POS, 151 Interlobar, Right, Station #11R PN11R 3 - = NEG 15 Interlobar, Left, Station #11L PN11L Lobar, Right, Station #1R PN1R Lobar, Left, Station #1L PN1L Segmental, Right, Station #13R PN13R 3

14 Page 14 of 16 Post-Surgical N form Field # Field Name Oracle column Length Values 156 Segmental,, Left, Station #13L PN13L Subsegmental, Right, Station #14R PN14R Subsegmental, Left, Station #14L PN14L Internal Mammary, Right PNINTMAMMARYR Internal Mammary, Left PNINTMAMMARYL Pericardial, Right PNPERICARDIALR 3 16 Pericardial, Left PNPERICARDIALL Peridiaphragmatic, Right PNPERIDIAPGHRR Peridiaphragmatic, Left PNPERIDIAPGHRL Intercostal, Right PNINTERCOSTALR Intercostal, Left PNINTERCOSTALL Retrocrual, Right PNRETROCRUALR Retrocrual, Left PNRETROCRUALL 3

15 Page 15 of 16 Post-Surgical M form Field # Field Name Oracle column Length Values Notes 169 Contralateral pleura PMETPLEURA 170 Contralateral lung PMETLUNG 171 Peritoneum PMETPERITONEUM 17 Intra-abdominal PMETINTRAABDOM 173 Bone PMETBONE 174 Liver parenchyma PMETLIVER 175 Brain PMETBRAIN 176 Other distant lymph nodes PMETOTHERDLN 177 Contralateral pleura - Biopsied or resected PMETPLEURABX 178 Contralateral lung - Biopsied or resected PMETLUNGBX 179 Peritoneum - Biopsied or resected PMETPERITONEUMBX 180 Intra-abdominal - Biopsied or resected PMETINTRAABDOMBX 181 Bone - Biopsied or resected PMETBONEBX 18 Liver parenchyma - Biopsied or resected PMETLIVERBX 183 Brain - Biopsied or resected PMETBRAINBX 184 Other distant lymph nodes - Biopsied or resected PMETOTHERDLNBX 185 Specify, Other distant sites PSPECIFYODSITES 00 alphanumeric alphanumeric 186 Other metastasis POTHERMETASTASIS No selection=null, Absent=ABSENT, Single=SINGLE, Multiple=MULT, Present=PRES, No data=nd No selection=null, Yes, resected=yres; Yes, biopsied, positive for malignancy=ybxpos; Yes, biopsied, negative for malignancy=ybxneg; No=N, No data=nd (optional additional information, when site of lesion is: SINGLE, MULT, or PRES) Document presence, number of lesions, clinical certainty factor, and whether biopsied/resected for any other sites of metastasis not listed above

16 Page 16 of 16 Follow Up form Oracle column Field # Field Name VARCHAR Values DDD: in (JAN, FEB, MAR, APR, MAY, JUN, 187 Date of Last Contact LCDATE DDMMMYYYY JUL, AUG, SEP, OCT, NOV, DEC) 188 Vital Status at Last Contact STATUSFU No selection=null, Alive=A, Dead=D, Lost to follow-up=l, No data=u

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Recommendations for the Reporting of Pleural Mesothelioma

Recommendations for the Reporting of Pleural Mesothelioma Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports

More information

Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma

Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma Based on AJCC/UICC TNM, 7th edition Protocol web posting date: February 1, 2011 Procedures Resection Authors

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious

More information

III. EXTENT OF DISEASE

III. EXTENT OF DISEASE Advanced Abstracting Lung Cancer III. EXTENT OF DISEASE Staging Systems and Documentation 1 Source: AJCC Cancer Staging Illustrations from the AJCC Cancer Staging Atlas. Springer, 2007. Used with permission.

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Date Guideline Created: April 2013 Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1.

More information

Thoracic Mesothelium. Protocol applies to malignant thoracic mesothelioma. Procedures Cytology (No Accompanying Checklist) Incisional Biopsy Resection

Thoracic Mesothelium. Protocol applies to malignant thoracic mesothelioma. Procedures Cytology (No Accompanying Checklist) Incisional Biopsy Resection Thoracic Mesothelium Protocol applies to malignant thoracic mesothelioma. Protocol revision date: January 2004 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist) Incisional

More information

How To Write Lung Cancer Data Standards For Nhs Scotland

How To Write Lung Cancer Data Standards For Nhs Scotland For reference only Do Not Use For more information contact: cdsis@nhs.net Lung Cancer Pathology Data Standards June 2008 National Clinical Dataset Development Programme (NCDDP) Support Team Information

More information

Ahmed Farouk Abd El-Hafez, MD

Ahmed Farouk Abd El-Hafez, MD Presented By Ahmed Farouk Abd El-Hafez, MD Lecturer of Cardiothoracic Surgery Assiut University Asbestos exposure : amphibole fibers especially crocidolite asbestos Nonasbestos Causes : Silicate fibers

More information

More than 2,500 people are diagnosed with mesothelioma in the UK each year.

More than 2,500 people are diagnosed with mesothelioma in the UK each year. This information is an extract from the booklet Understanding mesothelioma. You may find the full booklet helpful. We can send you a free copy see page 5. Contents Introduction Pleural mesothelioma Peritoneal

More information

Primary -Benign - Malignant Secondary

Primary -Benign - Malignant Secondary TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low

More information

Neoplasms of the LUNG and PLEURA

Neoplasms of the LUNG and PLEURA Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:

More information

Standards and datasets for reporting cancers. Dataset for the histological reporting of mesothelioma. April 2013

Standards and datasets for reporting cancers. Dataset for the histological reporting of mesothelioma. April 2013 Standards and datasets for reporting cancers Dataset for the histological reporting of mesothelioma April 2013 Authors Professor Andrew G Nicholson, Royal Brompton Hospital and Harefield NHS Trust Professor

More information

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,

More information

The Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging

The Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging 323.....:. #{149} :. #{149}..: #{149}. #{149}. :- : Received June 22, 1995; accepted after revision September 12, 1995. 1 Department of Radiology, Duke University Medical Center, Box 3808, Dunham, NC 2771

More information

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases Original Article Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases William G. Richards, PhD 1,2 ; John J. Godleski, MD 2,3 ; Beow Y.

More information

Survey of Mesothelioma Associated with Asbestos Exposure in Japan

Survey of Mesothelioma Associated with Asbestos Exposure in Japan The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics

More information

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC MESOTHELIOMA Not Just a Late Night Commercial Graciela Hoal, RN, MSN, ACNP-BC Saturday Session Thoracic Surgery Nurse Practitioner Greater Los Angeles Veteran Affairs Objectives Course Objectives: Discuss

More information

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Mesothelioma What is malignant mesothelioma? Malignant mesothelioma is a cancer that starts in cells in the linings of certain parts of the body, especially in the linings of the chest or abdomen.

More information

Understanding Pleural Mesothelioma

Understanding Pleural Mesothelioma Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Mesothelioma What is malignant mesothelioma? Malignant mesothelioma is a cancer that starts in cells in the linings of certain parts of the body, especially in the linings of the chest or abdomen.

More information

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS* COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun

More information

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS* COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun

More information

Pathology of lung cancer

Pathology of lung cancer Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu

More information

Plueral Malignancy: Radiologic-pathologic

Plueral Malignancy: Radiologic-pathologic Plueral Malignancy: Radiologic-pathologic Correlation Ritu R. Gill, MD Pleural Malignancies: Radiologic-Pathologic Correlation Ritu R Gill MD Brigham and Women s Hospital Boston, Massachusetts Pleural

More information

Lung cancer LUNG CANCER. Box 1 Clinical signs

Lung cancer LUNG CANCER. Box 1 Clinical signs 22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting

More information

Pleural and Chest Wall Tumors

Pleural and Chest Wall Tumors Pleural and Chest Wall Tumors Ritu Gill, MD, MPH Dr. Ritu R. Gill Department t of Radiology Brigham and Women s Hospital Harvard Medical School CLASSIFICATION OF CHEST WALL TUMORS Primary neoplasm of chest

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

The National Clinical Lung Cancer Audit (LUCADA)

The National Clinical Lung Cancer Audit (LUCADA) The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name

More information

How To Understand How Cancer Works

How To Understand How Cancer Works Mesothelioma Understanding your diagnosis Mesothelioma Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount of

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

More information

Sternotomy and removal of the tumor

Sternotomy and removal of the tumor Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a

More information

An Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder

An Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder CE Objectives and Evaluation Form appear on page 235. An Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder Patients with lung cancer can provide treatment challenges for even

More information

B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC

B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC Lung Cancer B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC EPIDEMIOLOGY The estimated incidence of lung cancer in Canada for 2007 is 23,300 with 12,400 occurring in

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

BIOBANK LPCE-NICE CHEST

BIOBANK LPCE-NICE CHEST BIOBANK LE-NIE HEST athologist : S. LASSALLE 01/03/2011 Time for frozen procedure : 10 mn LE / HU Unit atient : N LH 11-0004 N LB 11-0002 onsent : YES Age : 37 ID : TH ER Diagnosis and staging : Hodgkin

More information

Analysis One Code Desc. Transaction Amount. Fiscal Period

Analysis One Code Desc. Transaction Amount. Fiscal Period Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00

More information

Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8

Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant

More information

What is Mesothelioma?

What is Mesothelioma? What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and

More information

Malignant Pleural Mesothelioma. NCCN Guidelines for Patients

Malignant Pleural Mesothelioma. NCCN Guidelines for Patients Malignant Pleural Mesothelioma NCCN Guidelines for Patients Presented with support from the national law firm of Baron & Budd Also available at NCCN.com About this booklet Its purpose Learning that you

More information

In the last hundred years, lung cancer has risen from a

In the last hundred years, lung cancer has risen from a CONTINUING EDUCATION PET Evaluation of Lung Cancer* Tira Bunyaviroch, MD 1 ; and R. Edward Coleman, MD 2 1 Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts; and 2 Duke

More information

Understanding Your Surgical Options for Lung Cancer

Understanding Your Surgical Options for Lung Cancer Information Booklet for Patients Understanding Your Surgical Options for Lung Cancer Understanding Lung Cancer If you have just been diagnosed with lung cancer, this booklet will serve as an informational

More information

Cardiac Masses and Tumors

Cardiac Masses and Tumors Cardiac Masses and Tumors Question: What is the diagnosis? A. Aortic valve myxoma B. Papillary fibroelastoma C. Vegetation from Infective endocarditis D. Thrombus in transit E. None of the above Answer:

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year

More information

An Introduction to Anatomy and Physiology

An Introduction to Anatomy and Physiology An Introduction to Anatomy and Physiology Objectives Define anatomy and physiology Identify the levels of organization in organisms from simplest to most complex Identify the organ systems of the human

More information

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017 From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days

More information

Lung Cancer Workup and Staging

Lung Cancer Workup and Staging CHAPTER 16 Lung Cancer Workup and Staging Bernard J. Park and Valerie W. Rusch The Staging System Diagnosis and Staging History and Physical Examination Noninvasive Modalities Chest Radiography Sputum

More information

INFLAMMATORY PLEURAL EFFUSION

INFLAMMATORY PLEURAL EFFUSION PLEURA- LESIONS LESIONS OF PLEURA Primary Intra pleural bacterial infections Neoplasm (mesothelioma) Secondary A complication of some underlying disease PLEURAL EFFUSION Common manifestation of both primary

More information

A Practical Guide to Advances in Staging and Treatment of NSCLC

A Practical Guide to Advances in Staging and Treatment of NSCLC A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging

More information

Lung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine

Lung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Lung Cancer Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Alexandria, Egypt July 1-1 3, 2008 OBJECTIVES Describe and

More information

The Need for Accurate Lung Cancer Staging

The Need for Accurate Lung Cancer Staging The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives

More information

Pre-workshop exercise

Pre-workshop exercise Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please

More information

MALIGNANT PLEURAL MESOTHELIOMA TREATED IN CLINIC FOR PULMONARY DISEASES AND TUBERCULOSIS PODHRASTOVI IN TEN-YEAR PERIOD ( FROM 1998 TO 2007 )

MALIGNANT PLEURAL MESOTHELIOMA TREATED IN CLINIC FOR PULMONARY DISEASES AND TUBERCULOSIS PODHRASTOVI IN TEN-YEAR PERIOD ( FROM 1998 TO 2007 ) & MALIGNANT PLEURAL MESOTHELIOMA TREATED IN CLINIC FOR PULMONARY DISEASES AND TUBERCULOSIS PODHRASTOVI IN TEN-YEAR PERIOD ( FROM 1998 TO 2007 ) Vesna Čukić*, Aida Ustamujić, Vladimir Lovre, Hasan Žutić,

More information

Management of Non-Small Cell Lung Cancer Guide for General Practitioners

Management of Non-Small Cell Lung Cancer Guide for General Practitioners Management of n-small Cell Lung Cancer Guide for General Practitioners Clinical Stage I Cancer only in one lobe of lung and

More information

HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1

HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all

More information

Computed tomographic atlas for the new international lymph node map for lung cancer: A radiation oncologist perspective

Computed tomographic atlas for the new international lymph node map for lung cancer: A radiation oncologist perspective Practical Radiation Oncology (2013) 3, 54 66 www.practicalradonc.org Special Article Computed tomographic atlas for the new international lymph node map for lung cancer: A radiation oncologist perspective

More information

CHAPTER 4: LUNG CANCER DIAGNOSIS AND STAGING

CHAPTER 4: LUNG CANCER DIAGNOSIS AND STAGING CHAPTER 4: LUNG CANCER DIAGNOSIS AND STAGING INTRODUCTION The lungs are vital organs. Working with the heart and circulatory system, they provide lifesustaining oxygen and rid the body of carbon dioxide.

More information

Chapter 2 Staging of Breast Cancer

Chapter 2 Staging of Breast Cancer Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination

More information

III II II 111111111111111111111111111111111111111111 1 1111111111111 III. ge: /ears sex: Male Access

III II II 111111111111111111111111111111111111111111 1 1111111111111 III. ge: /ears sex: Male Access UUID : 10F97F63 - EE6F-448D - 98E1-8AAA21F55753 TCGA - TS-A7PB-01A-PR Redacted III II II 111111111111111111111111111111111111111111 1 1111111111111 III Date Receive III 11111111111111111 11111111111 II

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

System for Malignant Pleural Mesothelioma'

System for Malignant Pleural Mesothelioma' A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma' From the International Mesothelioma Interest Group* Study objective: Investigation of the behavior and treatment of diffuse

More information

How To Know When To Stage Lung Cancer

How To Know When To Stage Lung Cancer WHITE PAPER - SBRT for Non Small Cell Lung Cancer I. Introduction This white paper will focus on non-small cell lung carcinoma with sections one though six comprising a general review of lung cancer from

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. IV. THERAPY. I. NON SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. IV. THERAPY. I. NON SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. IV. THERAPY. I. NON SMALL CELL LUNG CANCER Prof. Alberto Riccardi TREATMENT OF LUNG CARCINOMA * overall treatment approach to

More information

Introduction to A&P (Chapter 1) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College. Eastern Campus

Introduction to A&P (Chapter 1) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College. Eastern Campus Introduction to A&P (Chapter 1) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Primary Sources for figures and content: Eastern Campus Marieb, E. N. Human Anatomy & Physiology

More information

General Information About Non-Small Cell Lung Cancer

General Information About Non-Small Cell Lung Cancer General Information About Non-Small Cell Lung Cancer Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing

More information

A912: Kidney, Renal cell carcinoma

A912: Kidney, Renal cell carcinoma A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type

More information

PLEURAL MESOTHELIOMA

PLEURAL MESOTHELIOMA PLEURAL MESOTHELIOMA PLEURAL MESOTHELIOMA By: Domenico Galetta Institute of Oncology Giovanni Paolo II I.R.C.C.S. Oncology Hospital of Bari, Italy Silvia Novello University of Torino, Italy San Luigi Hospital

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Table of Contents: Chapter 1: Screening for breast cancer in asymptomatic patients by Chris Comstock, MD and Marie Tartar, MD

Table of Contents: Chapter 1: Screening for breast cancer in asymptomatic patients by Chris Comstock, MD and Marie Tartar, MD Table of Contents: Chapter 1: Screening for breast cancer in asymptomatic patients by Chris Comstock, MD and Marie Tartar, MD Case 1: Breast cancer presenting as a small new mass on Case 2: Breast cancer

More information

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic

More information

Stage I, II Non Small Cell Lung Cancer

Stage I, II Non Small Cell Lung Cancer Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal

More information

Malignant Pleural Mesothelioma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration

Malignant Pleural Mesothelioma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration http://dx.doi.org/10.4046/trd.2013.74.2.74 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:74-78 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights

More information

STAGING CLASSIFICATION OF LUNG CANCER

STAGING CLASSIFICATION OF LUNG CANCER LUNG CANCER 0272 5231/02 $15.00.00 STAGING CLASSIFICATION OF LUNG CANCER A Critical Evaluation Clifton F. Mountain, MD In patients with lung cancer, the relationship between the anatomic extent of the

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

Introduction to A&P (Chapter 1) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus

Introduction to A&P (Chapter 1) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus Introduction to A&P (Chapter 1) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus Primary Sources for figures and content: Marieb, E. N. Human Anatomy & Physiology

More information

CT findings in Differential Diagnosis between Tuberculous Pleurisy and Malignant Effusion

CT findings in Differential Diagnosis between Tuberculous Pleurisy and Malignant Effusion CT findings in Differential Diagnosis between Tuberculous Pleurisy and Malignant Effusion Poster No.: E-0084 Congress: ESTI 2012 Type: Scientific Exhibit Authors: S. S. Shim, Y. Kim; Seoul/KR Keywords:

More information

Clinicopathological Study on Malignant Pleural Mesotheliomas

Clinicopathological Study on Malignant Pleural Mesotheliomas Table of Contents Clinicopathological Study on Malignant Pleural Mesotheliomas PL-4-03 Kenzo Hiroshima Kenzo Hiroshima 1, Akira Iyota 1, Kiyoshi Sibuya 1, Toshikazu Yusa 2, Takehiko Fujisawa 1 and Yukio

More information

Basic Data. 鍾 XX, female Age:59 y/o

Basic Data. 鍾 XX, female Age:59 y/o Basic Data 鍾 XX, female Age:59 y/o Chief complain for evaluation of the left pleural mass Clinical course This 59 years old lady Hypertension for 3 years, under herbal control. An episode of high BP up

More information

Male. Female. Death rates from lung cancer in USA

Male. Female. Death rates from lung cancer in USA Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita

More information

Administrative. Patient name Date compare with previous Position markers R-L, upright, supine Technical quality

Administrative. Patient name Date compare with previous Position markers R-L, upright, supine Technical quality CHEST X-RAY Administrative Patient name Date compare with previous Position markers R-L, upright, supine Technical quality AP or PA ( with x-ray beam entering from back of patient, taken at 6 feet) Good

More information

MANAGEMENT INFORMATION REPORT Department for Business Innovations & Skills (BIS)

MANAGEMENT INFORMATION REPORT Department for Business Innovations & Skills (BIS) MANAGEMENT INFORMATION REPORT Department for Business Innovations & Skills (BIS) Version 3.2 9/1/215 Clyde & Co 4 th Floor, Collingwood House, 3 Collingwood Street, Newcastle, NE1 1JW T: 191 229 223 F:

More information

CAFIS REPORT 2015.10

CAFIS REPORT 2015.10 CAFIS REPORT 2015.10 INDEX Message CAFIS Inbound 03-06 07-08 CAFIS Arch 09-10 CAFIS Brain 11-12 CAFIS Global 13-14 What We Do 15-16 About CAFIS 17-18 Services for Member Stores 19-34 Services for Card

More information

BIOBANK LPCE-NICE CHEST

BIOBANK LPCE-NICE CHEST HEST athologist :. BUTORI 08/01/2012 Time for frozen procedure : 45 mn LE / HU Unit atient : N LH 12-2304 N LB 12-0337 onsent : YES Age : 62 ID : MA H Diagnosis and staging : lung adenocarcinoma lymph

More information